New vaccine aims to shield adults from 24 pneumococcal strains
NCT ID NCT06678620
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 22 times
Summary
This study tests a new vaccine (PCV24) designed to protect against 24 types of pneumococcal bacteria, which can cause pneumonia and other infections. Around 992 adults aged 18 and older in China will receive the vaccine to check its safety and how well it triggers the immune system. The goal is to see if this vaccine works as well as existing ones.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pizhou Center for Disease Control and Prevention
Pizhou, Jiangsu, China
-
Xuzhou Center for Disease Control and Prevention
Xuzhou, Jiangsu, China
Conditions
Explore the condition pages connected to this study.